Neuropharmacologic evaluation of oxilapine, a potent psychoactive agent.
D000679:Amygdala / Q000187:drug effects; D000818:Animals; D001381:Azepines / Q000032:analysis / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D002415:Cats; D002531:Cerebellum / Q000032:analysis; D002540:Cerebral Cortex / Q000032:analysis; D004027:Diencephalon / Q000032:analysis; D004285:Dogs; D004558:Electric Stimulation; D004569:Electroencephalography; D005071:Evoked Potentials; D006624:Hippocampus / Q000187:drug effects; D008636:Mesencephalon / Q000032:analysis; D010643:Phenoxybenzamine / Q000494:pharmacology; D051381:Rats; D012018:Reflex / Q000187:drug effects*; D012023:Reflex, Monosynaptic / Q000187:drug effects; D012154:Reticular Formation / Q000187:drug effects; D012640:Seizures; D013116:Spinal Cord / Q000032:analysis; D013788:Thalamus / Q000187:drug effects*; D013997:Time Factors
D001381:Azepines; D010643:Phenoxybenzamine